A new CAR T cell therapy engineered to target mutant calreticulin successfully depleted disease-driving cells in myelofibrosis xenografts and human organoid models, offering a precision immunotherapy approach to this incurable blood disorder. The selective depletion while sparing normal hematopoietic cells strengthens the translational pathway toward human clinical trials. — Photo by Peter Burdon on Unsplash (Unsplash License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
